Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma

Anticancer Research

Volumn 16, Issue 5 A, 1996, Pages 3007-3012

  Lee, Wen Ying ^a   Jin, Ying Tai ^a   Tzeng, Ching Chern ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

cl 2; Breast carcinoma; Histological grading; p53

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GRADING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENES, BCL-2; GENES, P53; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029954952     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Wyllie AH: The biology of cell death in tumors. Anticancer Res 5: 131-136, 1985.
2. Sarraf CE and Bowen ID: Proportion of mitotic and apoptotic cells in a range of untreated experimental tumors. Cell Tissue Kinet 21: 45-49, 1988.
3. Raff MC: Social control of cell survival and cell death. Nature 356: 397-400, 1992.
4. Nunez G, London L, Hockenbery D, Alexander M, Mckearn JP and Korsmeyer SJ: Deregulated bcl-2 gene expression selectively prolongs survival of growth factor deprived hemopoietic cell lines. J Immunol 144: 3602-3610, 1990.
5. Chiou SK, Rao L and White E: bcl-2 blocks p53-dependent apoptosis. Mol cell Biol 14: 2556-2563, 1994.
6. Fisher TC, Milner AE, Gregory CD, Jackman GW, Aherne GW, Hartley JA, Dive C and Hickman JA: bcl-2 modulation of apoptosis induced by anticancer drugs: resistance pathways. Cancer Res 53: 3321-3326, 1993.
7. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O and Korsmeyer SJ: bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67: 879-888, 1991.
8. Yonish-Rouach E, Rensmitzki D, Lotem J, Sachs L, Kimchi A and Oren M: Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature 352: 345-347, 1991.
9. Lotem J and Sachs L: Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and - defective myeloid leukemic cells. Cell Growth and Differ 3: 41 -47, 1993.
10. Pezzella F, Morrison H, Jones M, Gatter KC, Lane D, Harris, AL and Mason DY: Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's Iymphoma. Histopathology 22: 39-44, 1992
11. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Fronzo GD, Rilke F and Veronesi U: The bcl-2 protein: a prognostic indicator strongly related to p53 in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
12. Leek RD, Kaklamanis L, Pezzella F, Gatter KC and Harris AL: bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69: 135-139, 1994.
13. Haldar S, Negrini M, Monne M, Sabbioni S and Croce CM: Down-Regulation of bcl-2 by p53 in breast cancer cells. Cancer Research 54: 2095-2097, 1994.
14. Weiss LM, Warnke RA, Sklar J and Cleary ML: Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. New Engl J Med 317: 1185-1189, 1987
15. Hockenbery DM, Zutler M, Hickey W, Nahn M and Korsmeyer SJ: bcl-2 protien is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci 88: 6961-6965, 1991
16. Lu QL, Elia G, Lucas S and Thomas JA: Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 53: 29-35, 1993.
17. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886, 1992.
18. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S and Buttyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993.
19. Bhargava V, Kell DL, Rijn M and Warnke RA: bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145: 535-540, 1994.
20. Gee JMW, Robertson JFR, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blarney RW and Nicholson RI: Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628, 1994.
21. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M and VialeG: The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Archiv 424: 47-51, 1994
22. Joensuu H, Pylkkanen L and Toikkanen S: bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145: 1191-1198, 1994.
23. Sierra A, Lloveras B, Castellsague X, Moreno L, Garcia-Ramirez Marta and Fabra A: bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 60: 54-60, 1995.
24. World Health Organization: Histological Typing of Breast Tumors. International histological classification of tumours No. 2, Second ed., Geneva, 1981.
25. Page DL, Anderson TJ and Elston CW: Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, eds. Diagnostic Histopathology of the breast. New York: Churchill Livingstone, 1987, pp. 300-311.
26. Vaux DL, Cory S and Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442, 1988.
27. McDonnell TJ, and Korsmeyer SJ: Progression from lymphoid hyperplasia to high grade malignant lymphoma in mice transgenic for the (14;18). Nature 9: 254-256, 1991 .
28. Piris MA, Pezella F, Martinez-Montero JC, Orradre JL, Villuendas R, SanchezBeato M, Cuena R, Cruz MA, Martinez B, Garrido MC, Gatter K, Aiello A, Delia D, Giardini R and Rilke F: p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 69: 337-341, 1994.
29. Hsu B, Marin MC, Brisbay S, McConnel K and McDonnell TJ: Expression of bcl-2 gene confers multidrug resistance to chemotherapy-induced cell death. Cancer Bull 46: 125-129, 1994.
30. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
31. Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, and Harris AL: Epidermal growth factor status as predictor of early recurrence of and death from breast cancer. Lancet 1: 1398-1402, 1987.